Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown. Since angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria and retard the rate of decline of renal function in chronic proteinuric nephropathies, including IgA nephropathy. The investigators conduct a randomized control study to evaluate the efficacy of ACE inhibitor in the treatment of early IgA nephropathy. Sixty patients with biopsy-proven IgA nephropathy and minimal proteinuria are recruited. They will be randomized to ramipril for 5 years or no treatment. Blood pressure, proteinuria and renal function will be monitored. This study will explore the effects of ACE inhibitor in the treatment of early IgA nephropathy, which is a major cause of dialysis-dependent renal failure.
Condition or disease
Biopsy-confirmed IgA NephropathyProteinuria Less Than 0.5 g Per DayNormal Blood PressureSerum Creatinine Below 120 Umol/l
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 25 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
age between 18 and 65
biopsy-confirmed IgA nephropathy
proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 umol/l
willingness to give written informed consent and willingness to participate in and comply with the study protocol
expected survival less than 2 years
pregnant or nursing mother, or women of childbearing potential without an effective method of birth control
history of myocardial infarction, congestive heart failure, or any other medical indication that necessitate the use of ACE inhibitor
evidence of clinically significant hepatic, gastrointestinal, autoimmune disease
history of malignancy, drug or alcohol abuse
participation in any previous trial on ACE inhibitor
taking other investigational drugs within the past 30 days
history of non-compliance to medical regimens and patients who are considered potentially unreliable
known history of sensitivity / allergy to ACE inhibitor